Silver sulfadiazine

Silver sulfadiazine
Clinical data
Trade names	Silvadene
Other names	(4-Amino-N-2-pyrimidinylbenzenesulfonamidato-NN,01)-silver, sulfadiazine silver, silver (I) sulfadiazine, 4-amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt
AHFS/Drugs.com	Monograph
MedlinePlus	a682598
Pregnancy; category	B (not recommended in late pregnancy);
Routes of; administration	Topical
ATC code	D06BA01 (WHO) ;
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	<1% (silver), 10% (sulfadiazine)
Protein binding	High (silver)
Excretion	2/3 kidney (sulfadiazine)
Identifiers
	IUPAC name Silver [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide;
CAS Number	22199-08-2 ;
PubChem CID	441244;
DrugBank	DB05245 ;
ChemSpider	390017 ;
UNII	W46JY43EJR;
KEGG	D00433 ;
ChEBI	CHEBI:9142 ;
ChEMBL	ChEMBL1382627 ;
CompTox Dashboard (EPA)	DTXSID4048646 ;
ECHA InfoCard	100.040.743
Chemical and physical data
Formula	C10H9AgN4O2S
Molar mass	357.14 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	285 °C (545 °F)
	SMILES [Ag+].O=S(=O)([N-]c1ncccn1)c2ccc(N)cc2;
	InChI InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1 ; Key:UEJSSZHHYBHCEL-UHFFFAOYSA-N ;
	(what is this?) (verify)

Silver sulfadiazine, sold under the brand Silvadene among others, is a topical antibiotic used in partial thickness and full thickness burns to prevent infection. Tentative evidence has found other antibiotics to be more effective, and therefore it is no longer generally recommended for second-degree (partial-thickness) burns, but is still widely used to protect third-degree (full-thickness) burns.

Common side effects include itching and pain at the site of use. Other side effects include low white blood cell levels, allergic reactions, bluish grey discoloration of the skin, red blood cell breakdown, or liver inflammation. Caution should be used in those allergic to other sulfonamides. It should not be used in pregnant women who are close to delivery. It is not recommended for use in children less than two months of age.

Silver sulfadiazine was discovered in the 1960s. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 279th most commonly prescribed medication in the United States, with more than 700,000 prescriptions.